BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 7997881)

  • 1. Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding.
    Thibodeau J; Cloutier I; Lavoie PM; Labrecque N; Mourad W; Jardetzky T; Sékaly RP
    Science; 1994 Dec; 266(5192):1874-8. PubMed ID: 7997881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1.
    Kim J; Urban RG; Strominger JL; Wiley DC
    Science; 1994 Dec; 266(5192):1870-4. PubMed ID: 7997880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular docking of superantigens with class II major histocompatibility complex proteins.
    Olson MA; Cuff L
    J Mol Recognit; 1997; 10(6):277-89. PubMed ID: 9770652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
    von Bonin A; Ehrlich S; Malcherek G; Fleischer B
    Eur J Immunol; 1995 Oct; 25(10):2894-8. PubMed ID: 7589089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell receptor-major histocompatibility complex class II interaction is required for the T cell response to bacterial superantigens.
    Labrecque N; Thibodeau J; Mourad W; Sékaly RP
    J Exp Med; 1994 Nov; 180(5):1921-9. PubMed ID: 7964467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
    Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
    Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered orientation of streptococcal superantigen (SSA) on HLA-DR1 allows unconventional regions to contribute to SSA Vbeta specificity.
    Stevens KR; Van M; Lamphear JG; Rich RR
    J Immunol; 1996 Dec; 157(11):4970-8. PubMed ID: 8943403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superantigens. Gazing into the crystal ball.
    Hsu PN; Huber BT
    Curr Biol; 1995 Mar; 5(3):235-7. PubMed ID: 7780728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective binding of bacterial toxins to major histocompatibility complex class II-expressing cells is controlled by invariant chain and HLA-DM.
    Lavoie PM; Thibodeau J; Cloutier I; Busch R; Sékaly RP
    Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6892-7. PubMed ID: 9192662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding sites for bacterial and endogenous retroviral superantigens can be dissociated on major histocompatibility complex class II molecules.
    Thibodeau J; Labrecque N; Denis F; Huber BT; Sékaly RP
    J Exp Med; 1994 Mar; 179(3):1029-34. PubMed ID: 8113671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superantigen natural affinity maturation revealed by the crystal structure of staphylococcal enterotoxin G and its binding to T-cell receptor Vbeta8.2.
    Fernández MM; Bhattacharya S; De Marzi MC; Brown PH; Kerzic M; Schuck P; Mariuzza RA; Malchiodi EL
    Proteins; 2007 Jul; 68(1):389-402. PubMed ID: 17427250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of HLA-DR1 beta chain residues critical for binding staphylococcal enterotoxins A and E.
    Karp DR; Long EO
    J Exp Med; 1992 Feb; 175(2):415-24. PubMed ID: 1370684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II.
    Hudson KR; Tiedemann RE; Urban RG; Lowe SC; Strominger JL; Fraser JD
    J Exp Med; 1995 Sep; 182(3):711-20. PubMed ID: 7650479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of MHC class II-associated peptides that promote the presentation of toxic shock syndrome toxin-1 to T cells.
    Hogan RJ; VanBeek J; Broussard DR; Surman SL; Woodland DL
    J Immunol; 2001 Jun; 166(11):6514-22. PubMed ID: 11359802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staphylococcal toxins bind to different sites on HLA-DR.
    Chintagumpala MM; Mollick JA; Rich RR
    J Immunol; 1991 Dec; 147(11):3876-81. PubMed ID: 1940373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staphylococcal enterotoxin B and toxic shock syndrome toxin-1 bind to distinct sites on HLA-DR and HLA-DQ molecules.
    Scholl PR; Diez A; Geha RS
    J Immunol; 1989 Oct; 143(8):2583-8. PubMed ID: 2551962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin 1.
    Hurley JM; Shimonkevitz R; Hanagan A; Enney K; Boen E; Malmstrom S; Kotzin BL; Matsumura M
    J Exp Med; 1995 Jun; 181(6):2229-35. PubMed ID: 7760008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple binding sites on the superantigen, staphylococcal enterotoxin B, imparts versatility in binding to MHC class II molecules.
    Soos JM; Johnson HM
    Biochem Biophys Res Commun; 1994 Jun; 201(2):596-602. PubMed ID: 8002991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of binding domains on the superantigen, toxic shock syndrome-1, for class II MHC molecules.
    Soos JM; Russell JK; Jarpe MA; Pontzer CH; Johnson HM
    Biochem Biophys Res Commun; 1993 Mar; 191(3):1211-7. PubMed ID: 8466498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification from a phage display library of peptides that bind to toxic shock syndrome toxin-1 and that inhibit its binding to major histocompatibility complex (MHC) class II molecules.
    Sato A; Ida N; Fukuyama M; Miwa K; Kazami J; Nakamura H
    Biochemistry; 1996 Aug; 35(32):10441-7. PubMed ID: 8756700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.